FDA’s Arista To India: What’s Your Everest?
This article was originally published in PharmAsia News
Executive Summary
For the quality-hit Indian drug industry, a senior investigator from the U.S. FDA has driven home a few candid messages – lead by example and clean up. Speaking at a conference in Mumbai, the representative pinned the responsibility on proactive corporate leadership to get the industry to follow best practices.